Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides has announced the approvals of two abbreviated new drug applications for Famotidine Injection USP, 20 mg/2mL single-dose vials and 40 mg/4mL and 200 mg/20mL multiple-dose vials.
Subscribe to our email newsletter
Famotidine Injection is indicated for the short term treatment of duodenal and gastric ulcers and gastroesophageal reflux disease. Famotidine Injection is therapeutically equivalent to the brand product Pepcid Injection of Merck.
Akorn-Strides is a joint venture that was formed in 2005 by Akorn, and Strides Arcolab. The primary mission for the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.